Sharma Amit, Reutter Heiko, Ellinger Jörg
1Department of Ophthalmology, University Clinic Bonn, Bonn, Germany; 2Department of Neurology, University Clinic Bonn, Bonn, Germany; 3Institute of Human Genetics, University Hospital of Bonn, Bonn, Germany; 4Department of Neonatology and Pediatric Intensive Care, Children's Hospital, University of Bonn, Bonn, Germany; 5Department of Urology, University Hospital Bonn, Bonn, Germany.
Curr Genomics. 2020 Jan;21(1):34-36. doi: 10.2174/1389202921666200102163422.
Nearly three decades ago, the association between Bladder cancer (BC) and DNA methylation has initially been reported. Indeed, in the recent years, the mechanism connecting these two has gained deeper insights. Still, the mediocre performance of DNA methylation markers in the clinics raises the major concern. Strikingly, whether it is the inter-individual methylation variations or the paucity of knowledge about methylation fingerprints lying within histologically distinct subtypes of BC requires critical discussion. In the future, besides identifying the initial causative factors, it will be important to illustrate the cascade of events that determines the fraction of the genome to convey altered methylation patterns specific towards each cancer type.
近三十年前，膀胱癌（BC）与DNA甲基化之间的关联首次被报道。事实上，近年来，连接这两者的机制有了更深入的见解。然而，DNA甲基化标志物在临床中的表现平平，这引发了人们的主要担忧。引人注目的是，无论是个体间的甲基化差异，还是对BC组织学不同亚型中甲基化指纹的了解不足，都需要进行批判性讨论。未来，除了确定最初的致病因素外，阐明决定基因组中特定于每种癌症类型的甲基化模式改变部分的一系列事件也将很重要。
